Active not recruiting × INDUSTRY × Lymphoma, Large-Cell, Anaplastic × Clear all
NCT06035497 2026-04-06

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Bristol-Myers Squibb

Phase 1/2 Active not recruiting
85 enrolled
NCT02568267 2026-03-06

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 2 FDA